NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.80 Consensus PT from Analysts

NewAmsterdam Pharma (NASDAQ:NAMS) has been assigned an average recommendation of “Buy” from the seven analysts that are covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $33.80.

A number of equities analysts have recently issued reports on NAMS shares. Needham & Company LLC began coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, August 28th. They set a “buy” rating and a $36.00 target price on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th.

NewAmsterdam Pharma Stock Down 0.9 %

Shares of NAMS stock opened at $15.92 on Tuesday. The stock’s 50-day moving average is $16.92 and its two-hundred day moving average is $19.25. NewAmsterdam Pharma has a 1 year low of $5.63 and a 1 year high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.08. The firm had revenue of $2.28 million for the quarter, compared to analysts’ expectations of $2.20 million. Research analysts forecast that NewAmsterdam Pharma will post -2.06 earnings per share for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds have recently modified their holdings of NAMS. Parkman Healthcare Partners LLC raised its position in NewAmsterdam Pharma by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock worth $3,359,000 after buying an additional 51,726 shares during the last quarter. TimesSquare Capital Management LLC acquired a new stake in NewAmsterdam Pharma in the first quarter valued at about $5,407,000. Opaleye Management Inc. purchased a new stake in NewAmsterdam Pharma in the 4th quarter valued at approximately $2,964,000. Jennison Associates LLC acquired a new position in NewAmsterdam Pharma during the 1st quarter worth approximately $22,015,000. Finally, Janus Henderson Group PLC purchased a new position in shares of NewAmsterdam Pharma during the 1st quarter worth approximately $15,018,000. 89.89% of the stock is owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.